PR
ProQR Therapeutics N.V.
PRQR · NASDAQ
$1.86 +1.92% (+$0.04)
1M -24.69%
Market Cap 170.8M €
P/E Ratio -
Div. Yield -
ROE 68.44%
Piotroski F-Score Weak
1/9Valuation
42 /100
Fair P/B 2.15x
P/S 9.20x
PEG N/A
Growth
78 /100
Growing Book val. growth 9.72%
Rev. growth 61.99%
FCF growth N/A
Profitability
20 /100
Weak FCF margin 270.78%
Op. margin 232.71%
Gross margin 92.33%
Quality
2 /100
Poor Asset turnover 0.14x
ROA 31.76%
ROIC 41.93%
Debt
100 /100
Low Current ratio 3.49x
Debt/Equity 0.17x
Net debt/EBITDA N/A
Stability
16 /100
Unstable Profitable years 0
EPS volatility 38.80%
Beta 0.03x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PRQR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Daniel Anton de Boer
Employees
166
Headquarters
Leiden
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report